Compare Ally Financial Inc (ALLY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ally Financial Inc vs TG Therapeutics Inc — how do they compare? Ally Financial Inc trades at $45.64 (market cap $13.97B), while TG Therapeutics Inc trades at $56.65 (market cap $8.74B). The key difference: Ally Financial Inc is the larger of the two by market cap, and Ally Financial Inc pays a 2.63% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ALLY | TGTX | |
|---|---|---|
Market Cap | $13.97B | $8.74B |
Sector | Financials | Health |
52-Week High | $47.25 | $59.06 |
52-Week Low | $35.96 | $26.39 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $8.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
TG Therapeutics (TGTX) trades at $57.12, down 3.28% on the day, amid mixed technical signals. The stock exhibits strong profitability with a net income margin of 65.95% and robust revenue growth, reaching $616.29 million in 2025. Recent positive news includes the initiation of a Phase II trial for Briumvi in schizophrenia and strong sales momentum, though recent quarterly EPS results have missed expectations. The technical outlook is bullish based on moving averages, but oscillators show bearish pressure with RSI levels indicating potential overbought conditions.
The investment outlook for TGTX is supported by strong analyst sentiment with 84.62% buy ratings and a consensus price target of $45.00, though the current price exceeds this target. Key opportunities include pipeline expansion and rising Briumvi demand, but risks involve clinical trial outcomes, competitive pressures, and cash flow volatility. Investors should weigh the high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
